HRT Eligibility and Safety

Who May Be a Good Candidate for HRT?

Hormone replacement therapy is generally considered most appropriate for women who are experiencing moderate to severe vasomotor symptoms (hot flashes and night sweats) that interfere with daily life, sleep, or well-being. Current medical guidelines from organizations such as The Menopause Society (formerly NAMS) suggest that for healthy women under 60 or within 10 years of menopause onset, the benefits of HRT typically outweigh the risks. This window is sometimes called the 'timing hypothesis' and has shaped how providers approach HRT in recent years.

• •Moderate to severe hot flashes or night sweats that affect sleep or daily functioning
• •Under 60 years old or within 10 years of your last menstrual period
• •No personal history of breast cancer, blood clots, or stroke
• •Premature menopause (before age 40) or early menopause (before age 45), where HRT may help protect long-term bone and cardiovascular health
• •Significant vaginal dryness or urinary symptoms not adequately managed with localized treatments
• •Bone density concerns where other treatments are not suitable

Who Should Exercise Caution or Avoid HRT?

HRT is not appropriate for every woman. Certain health conditions may increase the risks associated with hormone therapy, and a careful individual assessment is essential. Women with a personal history of breast cancer, endometrial cancer, blood clots, stroke, or active liver disease are generally advised against systemic HRT. Women with a family history of these conditions, or those with cardiovascular risk factors, should discuss the risk-benefit balance thoroughly with their provider.

How Has the Safety Picture Evolved?

The perception of HRT safety has shifted significantly over the past two decades. The Women's Health Initiative (WHI) study, published in 2002, raised concerns about the risks of HRT — particularly regarding breast cancer and cardiovascular events. However, subsequent re-analyses and newer research have provided a more nuanced picture. The original WHI findings were based largely on older women (average age 63) using a specific formulation of conjugated equine estrogen plus medroxyprogesterone acetate, which is no longer the standard of care.

Modern HRT practice tends to use bioidentical estradiol and micronized progesterone, start therapy closer to menopause onset (the 'timing hypothesis'), use the lowest effective dose, and favor transdermal delivery for women with higher blood clot risk. These shifts have led many menopause experts to conclude that for the right candidates, HRT remains a reasonable and effective treatment option when initiated at the appropriate time.

What About Compounded Hormones?

Some telehealth platforms offer compounded bioidentical hormones in addition to FDA-approved formulations. Compounded hormones are prepared by licensed pharmacies but are not FDA-approved and have not undergone the same testing for safety, efficacy, or consistency as FDA-approved products. While compounded options can provide useful flexibility in dosing or delivery format, it is important to understand this distinction. The Menopause Society and other major medical organizations generally recommend FDA-approved formulations when available.

Key Questions to Ask Your Provider

1. 1.Am I within the recommended window for starting HRT (under 60, or within 10 years of menopause)?
2. 2.Given my health history and risk factors, do the potential benefits of HRT outweigh the risks for me?
3. 3.Which formulation and delivery method (pills, patches, gels) would be most appropriate for my situation?
4. 4.Do I need progesterone in addition to estrogen, and if so, which type?
5. 5.How long should I plan to take HRT, and how will we reassess the decision over time?
6. 6.Are there non-hormonal alternatives I should consider, either instead of or in addition to HRT?